Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
NCT ID: NCT00900055
Last Updated: 2022-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
213 participants
OBSERVATIONAL
1975-06-30
2016-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
NCT00896740
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
NCT00146055
Gene Therapy for the Treatment of Fanconi's Anemia Type C
NCT00001399
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT00005900
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
NCT05012111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Identify the specific molecular function of the Fanconi anemia (FA) complementing gene products in hematopoietic progenitor cells from patients and normal volunteers.
* Identify functional defects in hematopoietic stromal cells, including macrophages, from patients with FA, and selected blood cancers as well as normal volunteers.
OUTLINE: Peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts are collected for loss-of-function and gain-of-function analysis related to the Fanconi anemia complementing gene.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microarray analysis
polyacrylamide gel electrophoresis
polymerase chain reaction
protein expression analysis
reverse transcriptase-polymerase chain reaction
western blotting
chromatography
high performance liquid chromatography
immunoenzyme technique
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets 1 of the following criteria:
* Diagnosis of one of the following:
* Fanconi's anemia requiring bone marrow biopsy as part of standard care (adults and children)
* Myeloproliferative disorder or myeloma (adults)
* Healthy volunteer, meeting 1 of the following criteria:
* Over 18 years of age
* Bone marrow transplant donor (children)
PATIENT CHARACTERISTICS:
* Hemoglobin \> 13 g/dL
* White blood cells (WBC) \> 4,000/mm³
* Platelet count \> 150,000/mm³
* No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or fungal)
* No known blood abnormality (healthy volunteers)
* No allergies to lidocaine or xylocaine
PRIOR CONCURRENT THERAPY:
* Not specified
1 Year
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
OHSU Knight Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Laura Newell
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Newell, MD
Role: PRINCIPAL_INVESTIGATOR
OHSU Knight Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OHSU-HEM-98030-L
Identifier Type: -
Identifier Source: secondary_id
IRB00000823
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.